Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 3Phase NA 1Phase 1/2 1Phase 1 1

Status

Completed 18Terminated 9Unknown 3Active not recruiting 3Not yet recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3Gastrointestinal 3

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 95Prostatic Neoplasms 58Multiple Myeloma 45Neoplasms 38Neoplasm Metastasis 33Ovarian Neoplasms 26Melanoma 24Urinary Bladder Neoplasms 23Lung Neoplasms 22Colorectal Neoplasms 22Recurrence 21Leukemia, Lymphocytic, Chronic, B-Cell 21Parkinson Disease 4, Autosomal Dominant Lewy Body 20Carcinoma, Renal Cell 20Carcinoma, Hepatocellular 17Triple Negative Breast Neoplasms 16Nasopharyngeal Carcinoma 16Lymphoma, Non-Hodgkin 16Stomach Neoplasms 15Leukemia, Myeloid, Acute 15Lymphoma 14Squamous Cell Carcinoma of Head and Neck 13Small Cell Lung Carcinoma 13Fallopian Tube Neoplasms 12Colonic Neoplasms 12Carcinoma 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Lymphoma, Large B-Cell, Diffuse 11Lymphoma, Follicular 11

Interventions

Sunitinib 3ripretinib 2Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Active not recruiting × Gastrointestinal Stromal Tumors × Clear all
NCT05208047 2026-05-22

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

Cogent Biosciences, Inc.

Phase 3 Active not recruiting
482 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT03673501 2026-02-05

INTRIGUE

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
453 enrolled 20 charts
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT05734105 2025-12-17

INSIGHT

Deciphera Pharmaceuticals, LLC

Phase 3 Active not recruiting
54 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡